

# Repurposing a Generic Tuberculosis Vaccine to Treat Type 1 Diabetes



## CWR Success Metrics

Research Aims Met

Benefit Seen in Patients


Publication of Results

Follow On Funding

Follow On Trials (impacting limited patients)

Impacting Patients Broadly

In 2008, Cures Within Reach funded **Dr. Denise Faustman** at **Massachusetts General Hospital / Harvard** to support repurposing of **the generic vaccine BCG** to help patients with **Type 1 Diabetes**. CWR first funded a screening trial, then a Phase I clinical trial. In 2018, Faustman published long-term results from this Phase I clinical trial, showing that multi-dosing BCG in long-term Type 1 patients can result in stable and long-term correction of blood sugars with just two doses of BCG, without further intervention. Patients who had longstanding Type 1 Diabetes before the Phase I trial had lowered blood sugar levels nearing the normal range for 5 consecutive years, without changing their care routine (no new pumps or diabetes monitoring devices). CWR funds are also supporting the Phase II clinical trial with 150 longstanding type 1 diabetes, which is fully enrolled and ongoing. Faustman is planning additional human clinical trials, including pediatric trials and trials in a broader selection of adults with longstanding type 1 diabetes.



## KEY FACTS

- CWR provided \$110,000 to fund the **animal trial and phase I / II human clinical trials** repurposing the BCG vaccine for Type 1 Diabetes patients.

## IMPACT

- Phase I study resulted in long-term restoration of blood sugars in Type 1 diabetic patients.
- Early CWR funding helped to leverage **>\$20 million in follow-on funding** from the Iacocca Foundation needed for this FDA registration trial.
- Faustman has expanded this BCG research to other diseases, including MS, fibromyalgia, Sjogren's syndrome and scleroderma.



CuresWithinReach



CUREACCELERATOR™